The results revealed a direct correlation between SIRI, a predictive index of response to therapy, and the soluble S100 and IL-6 proteins, biomarkers known to have a high frequency of elevated levels in melanoma patients who do not respond to therapy and are at high risk of disease progression/recurrence. The gene discussed is IL6; the disease is melanoma.